Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: tommysdad who wrote (469)	6/25/1999 2:10:00 AM
From: Spekulatius	Respond to of 3158

I do not see Genzyme as an acquisition candidate for a big drug company. Genzyme has a very successful niche strategy.It has unique product without competition which means there would not be much synergy. Thats why I do not believe a merger will happen. The pharma companies will more likely buy companies with products fitting into their own portfolio and which can be sold through their own salesforce. If anything, Genzyme should be on the acquisition side itself.